6O8I

BTK In Complex With Inhibitor

6O8I の概要

• エントリーDOI: 10.2210/pdb6o8i/pdb
• 分子名称: Tyrosine-protein kinase BTK, 4-[(3S)-3-{[(2E)-but-2-enoyl]amino}piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide (3 entities in total)
• 機能のキーワード: protein kinase, transferase, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 31800.52

構造登録者

Pokross, M.,Tebben, A.J.,Watterson, S.H. (登録日: 2019-03-11, 公開日: 2019-04-03, 最終更新日: 2024-11-20)

主引用文献

Watterson, S.H.,Liu, Q.,Beaudoin Bertrand, M.,Batt, D.G.,Li, L.,Pattoli, M.A.,Skala, S.,Cheng, L.,Obermeier, M.T.,Moore, R.,Yang, Z.,Vickery, R.,Elzinga, P.A.,Discenza, L.,D'Arienzo, C.,Gillooly, K.M.,Taylor, T.L.,Pulicicchio, C.,Zhang, Y.,Heimrich, E.,McIntyre, K.W.,Ruan, Q.,Westhouse, R.A.,Catlett, I.M.,Zheng, N.,Chaudhry, C.,Dai, J.,Galella, M.A.,Tebben, A.J.,Pokross, M.,Li, J.,Zhao, R.,Smith, D.,Rampulla, R.,Allentoff, A.,Wallace, M.A.,Mathur, A.,Salter-Cid, L.,Macor, J.E.,Carter, P.H.,Fura, A.,Burke, J.R.,Tino, J.A.
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
J. Med. Chem., 62:3228-3250, 2019

PubMed Abstract: Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clinical studies.

PubMed: 30893553
DOI: 10.1021/acs.jmedchem.9b00167

実験手法

X-RAY DIFFRACTION (1.42 Å)